ImmuneSensor Therapeutics develops best-in-class cGAS inhibitors that target the cGAS-STING pathway to modulate the innate immune system in patients with inflammatory and autoimmune diseases. By addressing the overactivity of the immune response, these therapeutics aim to reduce inflammation and improve patient outcomes.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The cGAS-STING pathway, responsible for activating innate immune defense, can become overactive due to cellular stress or damaged cells, leading to inflammation and autoimmune diseases. Current treatments often fail to specifically target this pathway, resulting in broad immunosuppression and potential side effects.
Solution
ImmuneSensor Therapeutics develops cGAS inhibitors designed to selectively modulate the cGAS-STING pathway, addressing the root cause of inflammation in autoimmune and inflammatory diseases. These inhibitors aim to suppress inflammation by targeting the overactive immune response triggered by cytosolic DNA. By specifically inhibiting cGAS, the company's therapeutics seek to provide a more targeted approach compared to broad immunosuppressants, potentially reducing side effects and improving patient outcomes. The company is leveraging its knowledge of the cGAS-STING pathway to create novel therapeutics.
Target Audience
The primary target audience includes patients suffering from inflammatory and autoimmune diseases, as well as healthcare providers seeking more targeted therapeutic options.
Features
- Selective cGAS inhibitors designed to modulate the innate immune system.
- Targets the cGAS-STING pathway to suppress inflammation and autoimmunity.
- Aims to provide a more targeted approach compared to broad immunosuppressants.